Mesothelioma
Oncology·MeSH: Mesothelioma
Prevalence
1.0 / 100K
Incidence
0.9 / 100K/yr
9 drugs in development·7 companies·22 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| Alimta® | ELI LILLY & Co (LLY) |
Phase 3(1)
| Drug | Company |
|---|---|
| Fianlimab | Merus N.V. (MRUS) |
Phase 2(3)
Phase 1(1)
| Drug | Company |
|---|---|
| CT-1119 | Carisma Therapeutics Inc. (CARM) |
Phase 1/Phase 2(3)
Compare drugs
Frequently asked questions
How many drugs are in development for Mesothelioma?
BioSniper tracks 9 drugs in development for Mesothelioma across 7 companies.
How many clinical trials target Mesothelioma?
There are 22 clinical trials targeting Mesothelioma tracked by BioSniper.
What is the prevalence of Mesothelioma?
The estimated prevalence of Mesothelioma is approximately 1.0 per 100,000 population.
Deep-dive into Mesothelioma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis